---

Not Medical Advice: This article is an educational review of scientific literature and does not account for individual health conditions. Always consult with healthcare professionals before making any health-related decisions.

NMN supplements had a moment. They're still having it, actually. The pitch is elegant: NAD+ is a coenzyme critical for mitochondrial function, and its levels decline with aging and chronic disorders ^{[5] [6]}. NMN is a direct precursor to NAD+ ^[5]. So you take NMN, NAD+ goes up, and the cellular machinery of youth hums along again. Simple.

Except for one problem. The tank fills up just fine. The engine doesn't seem to care.

The biomarker does exactly what it's supposed to

Let's give NMN its due. A systematic review covering 33 human intervention studies found that oral NMN consistently demonstrated biochemical target engagement, meaning circulating and cellular NAD-related metabolites went up, and the supplements were generally well tolerated over weeks to months ^[1]. A separate pharmacokinetic study indicated that achieving effective NAD augmentation may involve sustained oral administration over at least 2–4 weeks, with once-daily dosing appearing sufficient to maintain stable levels ^[7].

So NMN does its job. It gets into the body, it boosts NAD-related markers, and research suggests it has been generally well tolerated. If this were a drug development program, you'd call the Phase I data encouraging and move on to the question that actually matters: does raising NAD+ do anything a person would notice?

So why doesn't the obvious fix work?

This is where the story gets uncomfortable. That same systematic review of 113 studies found that effects on functional, metabolic, vascular, and other healthspan-relevant outcomes in humans were heterogeneous and often null or endpoint-specific ^[1]. Not "mixed but promising." Heterogeneous and often null.

Look at muscle. Sarcopenia, the age-related loss of muscle mass and function, is one of the conditions associated with declining NAD+ ^[6]. If restoring NAD+ were going to help anywhere, you'd expect it to show up here. A meta-analysis pooling randomized controlled trials of NMN in adults over 60 found no significant effects on skeletal muscle index, handgrip strength, gait speed, or chair-stand performance ^[2]. The confidence intervals weren't even close to interesting. Handgrip strength in pooled data showed a mean difference of 0.61 kg for left grip and 0.45 kg for right grip, neither statistically significant ^[2]. Narrative synthesis of additional outcomes told the same story: no improvement in knee extension strength, physical performance battery scores, or thigh muscle mass ^[2].

Maybe metabolism, then. A meta-analysis of eight RCTs testing NMN at dosages ranging from 250 to 2,000 mg per day over 14 days to 12 weeks found no significant benefit on fasting glucose, fasting insulin, glycated hemoglobin, insulin resistance, or lipid profiles ^[3]. The study populations were mostly relatively healthy, non-diabetic middle-aged and older adults, totaling 342 participants ^[3].

The numbers that don't add up to nothing

Here's what makes this genuinely puzzling rather than simply disappointing. One post hoc analysis of a randomized trial giving 300, 600, or 900 mg of daily NMN to 80 healthy middle-aged participants found that NMN-induced increases in blood NAD were associated with increases in hemoglobin, red blood cell count, and mean corpuscular hemoglobin concentration ^[4]. The authors suggested this could potentially indicate enhanced oxygen-carrying capacity ^[4].

That's an interesting signal. But zoom out. Higher baseline NAD levels in that same analysis were also associated with higher triglycerides, lower HDL, and higher liver transaminases ^[4]. The relationship between NAD and the body's metabolic machinery isn't a simple "more is better" equation. Some of those associations point in directions you wouldn't want to go.

There's also the problem of individual variation. The pharmacokinetic study noted considerable interindividual variability in NAD responses to precursor supplementation ^[7]. Two people take the same dose; their NAD levels might respond very differently. When you're running small trials and averaging results, that kind of noise can bury real effects in some subgroups while creating phantom effects in others.

What the rodents promised and the humans didn't deliver

The gap between animal and human data deserves attention. In rodent models, NAD+ augmentation was frequently associated with improvements in metabolic, mitochondrial, inflammatory, and functional outcomes ^[1]. Mice got better. People, at least so far, mostly haven't. The systematic review noted that even in rodents, effects varied across models and endpoints ^[1], but the overall picture was far more encouraging than what's emerged from human trials.

This is a familiar pattern in supplement research. A biological pathway matters. A precursor raises levels of a key molecule. Animal models look good. Then human trials show the body is more complicated than we assumed. The bottleneck might not be NAD+ supply. It might be enzyme activity downstream, tissue-specific delivery, competing metabolic demands, or any of a dozen other variables that a circulating blood level can't capture.

💊 Bottom Line

NMN is in an unusual position: it demonstrably does what supplement marketers claim at the biochemical level. NAD+ goes up. That part is real. What isn't real, at least not yet, is evidence that this biochemical change translates into the functional benefits people are paying for. Muscles don't get stronger ^[2]. Blood sugar doesn't improve ^[3]. The most comprehensive review to date calls the clinical effectiveness inconclusive and calls for larger, longer trials ^[1]. The honest read on NMN in 2026 is that we've proven the tank can be filled. We have not proven the engine runs better because of it. Until those longer trials arrive, the gap between NAD+ levels and actual human aging remains exactly that.

---

References

[1] Gallagher C, Emmanuel O. NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing research reviews. 2026. PMID: 41655607
https://pubmed.ncbi.nlm.nih.gov/41655607/

[2] Prokopidis K, Moriarty F, Bahat G, et al. The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis. Journal of cachexia, sarcopenia and muscle. 2025. PMID: 40275690
https://pubmed.ncbi.nlm.nih.gov/40275690/

[3] Chen F, Zhou D, Kong A, et al. Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials. Current diabetes reports. 2024. PMID: 39531138
https://pubmed.ncbi.nlm.nih.gov/39531138/

[4] Kuerec A, Wang W, Fokke K, et al. Association between blood nicotinamide adenine dinucleotide levels and blood laboratory parameters at baseline and after nicotinamide mononucleotide supplementation in middle-aged healthy individuals: post hoc analysis of a randomized, double-blinded, placebo-controlled clinical trial. GeroScience. 2025. PMID: 41162813
https://pubmed.ncbi.nlm.nih.gov/41162813/

[5] Yu B, Jing X, Jia L, et al. The versatile multi-functional substance NMN: its unique characteristics, metabolic properties, pharmacodynamic effects, clinical trials, and diverse applications. Frontiers in pharmacology. 2024. PMID: 39411062
https://pubmed.ncbi.nlm.nih.gov/39411062/

[6] Yusri K, Jose S, Vermeulen K, et al. The role of NAD⁺ metabolism and its modulation of mitochondria in aging and disease. npj metabolic health and disease. 2025. PMID: 40604314
https://pubmed.ncbi.nlm.nih.gov/40604314/

[7] Berven H, Svensen M, Eikeland H, et al. The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation. iScience. 2026. PMID: 41858901
https://pubmed.ncbi.nlm.nih.gov/41858901/